Minocycline’s protective effects against apoptosis in neurodegenerative diseases [45], [46] and fulminant hepatitis [89] have recently been attributed, in part, to reductions in caspase-3 expression and activation [46], [89]–[91]. The gene discussed is CASP3; the disease is neurodegenerative disease.